StockData
Johnson & Johnson logo

Johnson & Johnson

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q3 FY2026, quarter ended Sep 27, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3076% above fair value
$266.17−4.39 (-1.62%)

Close on Nov 3, 2026Market cap $641.44BP/E 40.4Yield 1.93%

Johnson & Johnson Other Pulmonary Hypertension medicines by Year

Other Pulmonary Hypertension medicines — Worldwide reported growth YoY (%) (%)

Johnson & Johnson Other Pulmonary Hypertension medicines: -12.7% in FY2025, down 20.6 pts from a year earlier.

Latest, FY2025
-12.7%
Period ended Dec 28, 2025
Change on a year earlier
-20.6 pts
7.9% in FY2024
History
6 years
Since FY2020
Sources
6
Documents cited below

Where the FY2025 figure comes from

“|| WW | 209 | 240 | (12.7) | (13.0) | 0.3”

Source: Form 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗

Reported in Form 8-K EX-99.2 Segment Sales Schedule.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedOther Pulmonary Hypertension medicines — Worldwide reported growth YoY (%) (%)Year on yearSource
FY2025Dec 28, 2025-12.7%-20.6 ptsForm 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗
FY2024Dec 29, 20247.9%+24.6 ptsForm 8-K (a2024q4exhibit991.htm, filed 2025-01-22) ↗
FY2023Dec 31, 2023-16.7%+4.1 ptsForm 8-K (a2023q4exhibit991.htm, filed 2024-01-23) ↗
FY2022Jan 1, 2023-20.8%-15.8 ptsForm 8-K (a2022q4exhibit991.htm, filed 2023-01-24) ↗
FY2021Jan 2, 2022-5.0%+7.8 ptsForm 8-K (a2021q4exhibit991.htm, filed 2022-01-25) ↗
FY2020Jan 3, 2021-12.8%–Form 8-K (a2020q4exhibit991.htm, filed 2021-01-26) ↗

Cite this data

StockData. (2026). Johnson & Johnson Other Pulmonary Hypertension medicines (%), annual FY2020–FY2025 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-other-ph-rep-yoy

See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.

See a number that looks wrong?